Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
TERMINATED
NCT04594694
PHASE2

Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Sponsor: Intercept Pharmaceuticals

View on ClinicalTrials.gov

Summary

Study to evaluate the efficacy, safety, and tolerability of investigational drug obeticholic acid (OCA) in combination with the investigational drug bezafibrate (BZF) in participants with Primary Biliary Cholangitis (PBC).

Official title: A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination With Bezafibrate in Subjects With Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2019-10-02

Completion Date

2025-10-14

Last Updated

2026-07-16

Healthy Volunteers

No

Interventions

DRUG

Obeticholic acid

5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily

DRUG

Bezafibrate 200 MG

200 mg IR tablet of Bezafibrate once daily for the remainder of the study

DRUG

OCA Placebo

One tablet daily for the remainder of the study

DRUG

Bezafibrate 200 mg Placebo

One tablet daily for the remainder of the study

DRUG

Bezafibrate 400 MG

400 mg SR tablet of Bezafibrate once daily for the remainder of the study

DRUG

Bezafibrate 400 mg Placebo

One tablet daily for the remainder of the study

DRUG

OCA

OCA one tablet will be administered.

DRUG

Bezafibrate

Bezafibrate one tablet will be administered.

Locations (33)

Flinders Medical Centre

Bedford Park, Perth, Australia

Royal Adelaide Hospital

Adelaide, Australia

UZ Gasthuisberg

Leuven, Belgium

Clinical Hospital Dubrava

Zagreb, Croatia

Zagreb University Hospital Center

Zagreb, Croatia

Hepato-Gastroenterologie HK, s.r.o.

Hradec Králové, Czechia

Artroscan s.r.o., Gastroenterologicka ambulance

Ostrava, Czechia

Research Site s.r.o.

Pilsen, Czechia

Tartu University Hospital

Tartu, Estonia

Hôpital Henri Mondor

Créteil, France

Centre Hospitalier Universitaire Grenoble

Grenoble, France

CHRU de Lille

Lille, France

Groupe Hospitalier Pitié Salpêtrière - Assistance publique - Hôpitaux de Paris

Paris, France

CHU Paris Est - Hopital Saint Antoine

Paris, France

Universitatsklinikum Hamburg-Eppendorf UKE

Hamburg, Germany

Medizinische Hochschule Hannover

Hanover, Germany

Department of Medicine and Research Laboratory of Internal Medicine, University Hospital of Larissa

Larissa, Greece

Budai Hepatologiai Centrum (BHC)

Budapest, Hungary

DEOEC II. sz. Belgyógyászati Klinika

Debrecen, Hungary

Hadassah Ein-Karem Medical Center - Liver unit

Jerusalem, Israel

Tel Aviv Surasky Medical Center

Tel Aviv, Israel

Hospital of Lithuanian University of Health Sciences, Kauno Klinikos

Kaunas, Lithuania

Vlinius University

Vilnius, Lithuania

Academisch Medisch Centrum

Amsterdam, Netherlands

Universitetet i Oslo - Akershus Universitetssykehus (AHUS)

Loerenskog, Norway

Narodowy Instytut Onkologii, Klinika Gastroenterologii Onkologicznej

Warsaw, Poland

Pusan National University Hospital

Busan, South Korea

Kyungpook National University Hospital

Daegu, South Korea

Fundacio Clinic Per La Recerca Biomedica

Barcelona, Spain

Consorcio Hospital General Universitario

Valencia, Spain

Hull University Teaching Hospitals NHS Trust

Hull, United Kingdom

Institute of Cellular Medicine, Newcastle University

Newcastle upon Tyne, United Kingdom

John Radcliffe Hospital

Oxford, United Kingdom